A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
Status:
Completed
Trial end date:
2020-04-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the recommended dose and evaluate the
effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the
change from baseline in Movement disorder society-unified Parkinson's disease rating
scale(MDS-UPDRS) partIII score between KW-6356 and placebo in patients with Parkinson's
disease on treatment with Levodopa-containing preparations as an adjunctive therapy.